Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Saved in:
| Title: | Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. |
|---|---|
| Authors: | Bloehdorn J; Department of Internal Medicine III, University of Ulm, Ulm, Germany. johannes.bloehdorn@gmail.com., Braun A; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Taylor-Weiner A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Jebaraj BMC; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Robrecht S; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Pan H; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA., Giza A; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Akylzhanova G; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Holzmann K; Genomics Core Facility, Ulm University, Ulm, Germany., Scheffold A; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Johnston HE; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Yeh RF; Biostatistics, Genentech Inc., South San Francisco, CA, USA., Klymenko T; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Tausch E; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Eichhorst B; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Bullinger L; Medical Clinic for Hematology, Oncology and Tumor Biology, Charité University Hospital, Berlin, Germany., Fischer K; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Weisser M; Roche Pharma Research and Early Development, Penzberg, Germany., Robak T; Department of Hematology, Medical University of Lodz, Lodz, Poland., Schneider C; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Gribben J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Dahal LN; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.; Department of Pharmacology and Therapeutics, Faculty of Life and Health Sciences, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Carter MJ; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Elemento O; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Landau DA; Cancer Genomics and Evolutionary Dynamics, Weill Cornell Medicine, New York, NY, USA.; New York Genome Center, New York, NY, USA., Neuberg DS; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Cragg MS; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Hallek M; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Wu CJ; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Stilgenbauer S; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Mertens D; Department of Internal Medicine III, University of Ulm, Ulm, Germany. d.mertens@dkfz-heidelberg.de.; German Cancer Research Center (DKFZ), Heidelberg, Germany. d.mertens@dkfz-heidelberg.de. |
| Source: | Nature communications [Nat Commun] 2021 Sep 13; Vol. 12 (1), pp. 5395. Date of Electronic Publication: 2021 Sep 13. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
